John D Imig

List of Publications by Year
in descending order

261 papers	11,400 citations	20759 60 h-index	40881 93 g-index
323 all docs	323 docs citations	323 times ranked	7709 citing authors

#	Article	IF	Citations
1	Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nature Reviews Drug Discovery, 2009, 8, 794-805.	21.5	527
2	Soluble Epoxide Hydrolase Inhibition Lowers Arterial Blood Pressure in Angiotensin II Hypertension. Hypertension, 2002, 39, 690-694.	1.3	373
3	Epoxides and Soluble Epoxide Hydrolase in Cardiovascular Physiology. Physiological Reviews, 2012, 92, 101-130.	13.1	302
4	Immune and Inflammatory Role in Renal Disease. , 2013, 3, 957-976.		254
5	Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2001, 98, 5211-5216.	3.3	228
6	An Orally Active Epoxide Hydrolase Inhibitor Lowers Blood Pressure and Provides Renal Protection in Salt-Sensitive Hypertension. Hypertension, 2005, 46, 975-981.	1.3	223
7	Angiotensin II hypertension is attenuated in interleukin-6 knockout mice. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H935-H940.	1.5	218
8	Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases. American Journal of Physiology - Renal Physiology, 2005, 289, F496-F503.	1.3	208
9	Receptor-Mediated Intrarenal Angiotensin II Augmentation in Angiotensin IIâ€“Infused Rats. Hypertension, 1996, 28, 669-677.	1.3	165
10	Ang II Accumulation in Rat Renal Endosomes During Ang II-Induced Hypertension. Hypertension, 2002, 39, 116-121.	1.3	160
11	Identification of a Putative Microvascular Oxygen Sensor. Circulation Research, 1996, 79, 54-61.	2.0	154
12	Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage. Journal of the American Society of Nephrology: JASN, 2004, 15, 1244-53.	3.0	153
13	Eicosanoid regulation of the renal vasculature. American Journal of Physiology - Renal Physiology, 2000, 279, F965-F981.	1.3	151
14	Physiological role for P2X1 receptors in renal microvascular autoregulatory behavior. Journal of Clinical Investigation, 2003, 112, 1895-1905.	3.9	144
15	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 9038-9043.	3.3	130
16	Endothelial expression of human cytochrome P450 epoxygenases lowers blood pressure and attenuates hypertensionâ€induced renal injury in mice. FASEB Journal, 2010, 24, 3770-3781.	0.2	126
17	Thioredoxin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia, 2014, 57, 413-423.	2.9	125
18	TNF-Î± inhibition reduces renal injury in DOCA-salt hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2008, 294, R76-R83.	0.9	121

#	Article	IF	Citations
19	Soluble epoxide hydrolase gene deletion attenuates renal injury and inflammation with DOCA-salt hypertension. American Journal of Physiology - Renal Physiology, 2009, 297, F740-F748.	1.3	121
20	Early diabetes mellitus stimulates proximal tubule renin mRNA expression in the rat. Kidney International, 2000, 58, 2320-2330.	2.6	118
21	An Epoxide Hydrolase Inhibitor, 12-(3-Adamantan-1-yl-ureido)dodecanoic Acid (AUDA), Reduces Ischemic Cerebral Infarct Size in Stroke-Prone Spontaneously Hypertensive Rats. Journal of Cardiovascular Pharmacology, 2005, 46, 842-848.	0.8	117
22	Epoxygenase Metabolites Contribute to Nitric Oxide-Independent Afferent Arteriolar Vasodilation in Response to Bradykinin. Journal of Vascular Research, 2001, 38, 247-255.	0.6	110
23	Tumor Necrosis Factor Î± Blockade Increases Renal Cyp2c23 Expression and Slows the Progression of Renal Damage in Salt-Sensitive Hypertension. Hypertension, 2006, 47, 557-562.	1.3	110
24	Roles of the cytochrome P450 arachidonic acid monooxygenases in the control of systemic blood pressure and experimental hypertension. Kidney International, 2007, 72, 683-689.	2.6	108
25	Epoxyeicosatrienoic Acid Analogs and Vascular Function. Current Medicinal Chemistry, 2010, 17, 1181-1190.	1.2	103
26	Decreased Renal Cytochrome P450 2C Enzymes and Impaired Vasodilation Are Associated With Angiotensin Salt-Sensitive Hypertension. Hypertension, 2003, 41, 709-714.	1.3	102
27	Soluble Epoxide Inhibition Is Protective Against Cerebral Ischemia via Vascular and Neural Protection. American Journal of Pathology, 2009, 174, 2086-2095.	1.9	102
28	Renal Uptake of Circulating Angiotensin II in Val5-Angiotensin II Infused Rats Is Mediated by AT1 Receptor. American Journal of Hypertension, 1998, 11, 570-578.	1.0	101
29	Renal Accumulation of Circulating Angiotensin II in Angiotensin IIâ€“Infused Rats. Hypertension, 1996, 27, 658-662.	1.3	100
30	Endothelial Dysfunction and the Development of Renal Injury in Spontaneously Hypertensive Rats Fed a High-Fat Diet. Hypertension, 2008, 51, 352-359.	1.3	99
31	Antihypertensive effects of selective prostaglandin E2 receptor subtype 1 targeting. Journal of Clinical Investigation, 2007, 117, 2496-2505.	3.9	94
32	Afferent Arteriolar Vasodilation to the Sulfonimide Analog of 11,12-Epoxyeicosatrienoic Acid Involves Protein Kinase A. Hypertension, 1999, 33, 408-413.	1.3	93
33	Anti-inflammatory Effects of Ï‰-3 Polyunsaturated Fatty Acids and Soluble Epoxide Hydrolase Inhibitors in Angiotensin-IIâ€“Dependent Hypertension. Journal of Cardiovascular Pharmacology, 2013, 62, 285-297.	0.8	92
34	ETA and ETB receptors differentially modulate afferent and efferent arteriolar responses to endothelin. British Journal of Pharmacology, 2005, 146, 1019-1026.	2.7	89
35	Cardiovascular Therapeutic Aspects of Soluble Epoxide Hydrolase Inhibitors. Cardiovascular Drug Reviews, 2006, 24, 169-188.	4.4	86
36	Increased RhoA/Rho-Kinase Signaling Mediates Spontaneous Tone in Aorta from Angiotensin II-Induced Hypertensive Rats. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 288-295.	1.3	85

#	Article	IF	Citations
37	Eicosanoids and renal vascular function in diseases. Clinical Science, 2006, 111, 21-34.	1.8	83
38	Normalization of the Ovarian Cancer Microenvironment by SPARC. Molecular Cancer Research, 2007, 5, 1015-1030.	1.5	83
39	Cytochrome P450 and Cyclooxygenase Metabolites Contribute to the Endothelin-1 Afferent Arteriolar Vasoconstrictor and Calcium Responses. Hypertension, 2000, 35, 307-312.	1.3	81
40	Inhibition of soluble epoxide hydrolase prevents renal interstitial fibrosis and inflammation. American Journal of Physiology - Renal Physiology, 2014, 307, F971-F980.	1.3	81
41	Neuronal nitric oxide synthase modulates rat renal microvascular function. American Journal of Physiology - Renal Physiology, 1998, 274, F516-F524.	1.3	79
42	Early Onset Salt-Sensitive Hypertension in Bradykinin B ₂ Receptor Null Mice. Hypertension, 1999, 34, 176-180.	1.3	78
43	Contribution of cytochrome P450 epoxygenase and hydroxylase pathways to afferent arteriolar autoregulatory responsiveness. British Journal of Pharmacology, 1999, 127, 1399-1405.	2.7	78
44	Obesity is the major contributor to vascular dysfunction and inflammation in high-fat diet hypertensive rats. Clinical Science, 2010, 118, 291-301.	1.8	76
45	Administration of a substituted adamantyl urea inhibitor of soluble epoxide hydrolase protects the kidney from damage in hypertensive Gotoâ€“Kakizaki rats. Clinical Science, 2009, 116, 61-70.	1.8	75
46	Obesity, Insulin Resistance, and Renal Function. Microcirculation, 2007, 14, 349-362.	1.0	72
47	Unraveling the Mystery of Goldblatt Hypertension. Physiology, 1998, 13, 170-176.	1.6	71
48	Decreased epoxygenase and increased epoxide hydrolase expression in the mesenteric artery of obese Zucker rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2005, 288, R188-R196.	0.9	71
49	Epoxyeicosatrienoic Acids, Hypertension, and Kidney Injury. Hypertension, 2015, 65, 476-482.	1.3	71
50	Chemokine Receptor 2b Inhibition Provides Renal Protection in Angiotensin IIâ€“Salt Hypertension. Hypertension, 2007, 50, 1069-1076.	1.3	70
51	Novel orally active epoxyeicosatrienoic acid (EET) analogs attenuate cisplatin nephrotoxicity. FASEB Journal, 2013, 27, 2946-2956.	0.2	70
52	Fructose Stimulates Na/H Exchange Activity and Sensitizes the Proximal Tubule to Angiotensin II. Hypertension, 2014, 63, e68-73.	1.3	68
53	Renal endosomes contain angiotensin peptides, converting enzyme, and AT_{1A}receptors. American Journal of Physiology - Renal Physiology, 1999, 277, F303-F311.	1.3	67
54	Prospective for cytochrome P450 epoxygenase cardiovascular and renal therapeutics. , 2018, 192, 1-19.		67

#	Article	IF	Citations
55	Downregulation of Renal CYP-Derived Eicosanoid Synthesis in Rats With Diet-Induced Hypertension. Hypertension, 2003, 42, 594-599.	1.3	66
56	Identification of Novel Endogenous Cytochrome P450 Arachidonate Metabolites with High Affinity for Cannabinoid Receptors. Journal of Biological Chemistry, 2008, 283, 24514-24524.	1.6	65
57	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocin-induced type 1 diabetes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 301, R1307-R1317.	0.9	65
58	Cytochrome P450 eicosanoids and cerebral vascular function. Expert Reviews in Molecular Medicine, 2011, 13, e7.	1.6	64
59	Pharmacological inhibition of soluble epoxide hydrolase prevents renal interstitial fibrogenesis in obstructive nephropathy. American Journal of Physiology - Renal Physiology, 2015, 308, F131-F139.	1.3	64
60	Inhibition of soluble epoxide hydrolase by <i>cis</i>-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertension. Clinical Science, 2012, 122, 513-527.	1.8	63
61	Epoxyeicosatrienoic acid analogue lowers blood pressure through vasodilation and sodium channel inhibition. Clinical Science, 2014, 127, 463-474.	1.8	63
62	Afferent and Efferent Arteriolar Vasoconstriction to Angiotensin II and Norepinephrine Involves Release of Ca ²⁺ From Intracellular Stores. Hypertension, 1997, 29, 222-227.	1.3	62
63	Renal autoregulation in P2X1 knockout mice. Acta Physiologica Scandinavica, 2004, 181, 445-453.	2.3	62
64	Epoxyeicosatrienoic Acids and 20-Hydroxyeicosatetraenoic Acid on Endothelial and Vascular Function. Advances in Pharmacology, 2016, 77, 105-141.	1.2	62
65	Afferent Arteriolar Dilation to 11, 12-EET Analogs Involves PP2A Activity and Ca2 +-Activated K+Channels. Microcirculation, 2008, 15, 137-150.	1.0	61
66	Multi-Target Approaches in Metabolic Syndrome. Frontiers in Pharmacology, 2020, 11, 554961.	1.6	59
67	Cyclooxygenase-2 Modulates Afferent Arteriolar Responses to Increases in Pressure. Hypertension, 1999, 34, 843-847.	1.3	58
68	SPARC Ameliorates Ovarian Cancer-Associated Inflammation. Neoplasia, 2008, 10, 1092-1104.	2.3	58
69	Epoxyeicosatrienoic acids, 20-hydroxyeicosatetraenoic acid, and renal microvascular function. Prostaglandins and Other Lipid Mediators, 2013, 104-105, 2-7.	1.0	58
70	Secreted Protein Acidic and Rich in Cysteine Deficiency Ameliorates Renal Inflammation and Fibrosis in Angiotensin Hypertension. American Journal of Pathology, 2007, 171, 1104-1112.	1.9	56
71	Orally Active Epoxyeicosatrienoic Acid Analog Attenuates Kidney Injury in Hypertensive Dahl Saltâ€"Sensitive Rat. Hypertension, 2013, 62, 905-913.	1.3	56
72	Enhanced renal microvascular reactivity to angiotensin II in hypertension is ameliorated by the sulfonimide analog of 11,12-epoxyeicosatrienoic acid. Journal of Hypertension, 2001, 19, 983-992.	0.3	55

#	Article	IF	Citations
73	Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor Î³ agonist improve vascular function and decrease renal injury in hypertensive obese rats. Experimental Biology and Medicine, 2012, 237, 1402-1412.	1.1	54
74	Increased blood pressure in mice lacking cytochrome P450 2J5. FASEB Journal, 2008, 22, 4096-4108.	0.2	53
75	Targeting Epoxides for Organ Damage in Hypertension. Journal of Cardiovascular Pharmacology, 2010, 56, 329-335.	0.8	53
76	Role of Renal Nerves in Afferent Arteriolar Reactivity in Angiotensin-Induced Hypertension. Hypertension, 1997, 29, 442-449.	1.3	52
77	Cyclooxygenase-2 participates in tubular flow-dependent afferent arteriolar tone: interaction with neuronal NOS. American Journal of Physiology - Renal Physiology, 1998, 275, F605-F612.	1.3	52
78	Eicosanoids and renal damage in cardiometabolic syndrome. Expert Opinion on Drug Metabolism and Toxicology, 2008, 4, 165-174.	1.5	52
79	The Cyp2c44 Epoxygenase Regulates Epithelial Sodium Channel Activity and the Blood Pressure Responses to Increased Dietary Salt. Journal of Biological Chemistry, 2014, 289, 4377-4386.	1.6	51
80	Contribution of prostaglandin EP₂receptors to renal microvascular reactivity in mice. American Journal of Physiology - Renal Physiology, 2002, 283, F415-F422.	1.3	50
81	PPAR-Î± activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. American Journal of Physiology - Heart and Circulatory Physiology, 2006, 290, H2187-H2195.	1.5	49
82	Glomerular Expression of Kidney Injury Molecule-1 and Podocytopenia in Diabetic Glomerulopathy. American Journal of Nephrology, 2011, 34, 268-280.	1.4	49
83	Development of Epoxyeicosatrienoic Acid Analogs with in Vivo Anti-Hypertensive Actions. Frontiers in Physiology, 2010, 1, 157.	1.3	47
84	12-Hydroxyeicosatetraenoic acid participates in angiotensin II afferent arteriolar vasoconstriction by activating L-type calcium channels. Journal of Lipid Research, 2003, 44, 2391-2399.	2.0	45
85	Altered Kidney CYP2C and Cyclooxygenaseâ€2 Levels Are Associated with Obesityâ€Related Albuminuria. Obesity, 2004, 12, 1278-1289.	4.0	45
86	Rofecoxib decreases renal injury in obese Zucker rats. Clinical Science, 2004, 107, 561-570.	1.8	45
87	Protein phosphatase 2A and Ca2+-activated K+ channels contribute to 11,12-epoxyeicosatrienoic acid analog mediated mesenteric arterial relaxation. Prostaglandins and Other Lipid Mediators, 2007, 83, 50-61.	1.0	45
88	Interactive Nitric Oxideâ€“Angiotensin II Influences on Renal Microcirculation in Angiotensin IIâ€“Induced Hypertension. Hypertension, 1998, 31, 1255-1260.	1.3	44
89	Afferent arteriolar reactivity to angiotensin II is enhanced during the early phase of angiotensin II hypertension. American Journal of Hypertension, 2000, 13, 810-818.	1.0	44
90	Simvastatin and tempol protect against endothelial dysfunction and renal injury in a model of obesity and hypertension. American Journal of Physiology - Renal Physiology, 2010, 298, F86-F94.	1.3	44

#	Article	IF	Citations
91	Hypertension Is a Major Contributor to 20-Hydroxyeicosatetraenoic Acidâ€"Mediated Kidney Injury in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 597-610.	3.0	44
92	ACE Inhibition and Bradykinin-Mediated Renal Vascular Responses. Hypertension, 2004, 43, 533-535.	1.3	43
93	Substituted Adamantyl-Urea Inhibitors of the Soluble Epoxide Hydrolase Dilate Mesenteric Resistance Vessels. Journal of Pharmacology and Experimental Therapeutics, 2006, 318, 1307-1314.	1.3	43
94	Combined inhibition of 20-hydroxyeicosatetraenoic acid formation and of epoxyeicosatrienoic acids degradation attenuates hypertension and hypertensioninduced end-organ damage in Ren-2 transgenic rats. Clinical Science, 2010, 118, 617-632.	1.8	43
95	Endothelin-Mediated Calcium Signaling in Preglomerular Smooth Muscle Cells. Hypertension, 2000, 35, 280-286.	1.3	42
96	The CYP450 hydroxylase pathway contributes to P2X receptor-mediated afferent arteriolar vasoconstriction. American Journal of Physiology - Heart and Circulatory Physiology, 2001, 281, H2089-H2096.	1.5	42
97	Novel Nitric Oxide Synthaseâ€"Dependent Mechanism of Vasorelaxation in Small Arteries From Hypertensive Rats. Hypertension, 2007, 49, 893-901.	1.3	42
98	Orally Active Epoxyeicosatrienoic Acid Analogs. Journal of Cardiovascular Pharmacology, 2017, 70, 211-224.	0.8	42
99	Epoxygenase Metabolites: Epithelial and Vascular Actions. Molecular Biotechnology, 2000, 16, 233-252.	1.3	41
100	Calcium Mobilization Contributes to Pressure-Mediated Afferent Arteriolar Vasoconstriction. Hypertension, 1998, 31, 421-428.	1.3	40
101	Purinoceptor-Mediated Calcium Signaling in Preglomerular Smooth Muscle Cells. Hypertension, 1999, 33, 195-200.	1.3	40
102	Calcium signaling pathways utilized by P2X receptors in freshly isolated preglomerular MVSMC. American Journal of Physiology - Renal Physiology, 2001, 280, F1054-F1061.	1.3	40
103	A novel dual PPAR-Î³ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes. Diabetologia, 2018, 61, 2235-2246.	2.9	40
104	RenalAT1Receptor Protein Expression During the Early Stage of Diabetes Mellitus. International Journal of Experimental Diabetes Research, 2002, 3, 97-108.	1.0	39
105	Impaired Ca 2+ Signaling Attenuates P2X Receptorâ€"Mediated Vasoconstriction of Afferent Arterioles in Angiotensin II Hypertension. Hypertension, 2005, 46, 562-568.	1.3	39
106	Mechanisms involved in oleamide-induced vasorelaxation in rat mesenteric resistance arteries. European Journal of Pharmacology, 2009, 607, 143-150.	1.7	37
107	Inhibition of soluble epoxide hydrolase improves the impaired pressureâ€"natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. Journal of Hypertension, 2011, 29, 1590-1601.	0.3	37
108	Inhibition of soluble epoxide hydrolase is renoprotective in 5/6 nephrectomized Renâ€2 transgenic hypertensive rats. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 227-237.	0.9	37

#	Article	IF	Citations
109	A dual COX-2/sEH inhibitor improves the metabolic profile and reduces kidney injury in Zucker diabetic fatty rat. Prostaglandins and Other Lipid Mediators, 2016, 125, 40-47.	1.0	37
110	Epoxyeicosatrienoic Acid Analog Decreases Renal Fibrosis by Reducing Epithelial-to-Mesenchymal Transition. Frontiers in Pharmacology, 2017, 8, 406.	1.6	36
111	Eicosanoid blood vessel regulation in physiological and pathological states. Clinical Science, 2020, 134, 2707-2727.	1.8	36
112	p66Shc regulates renal vascular tone in hypertension-induced nephropathy. Journal of Clinical Investigation, 2016, 126, 2533-2546.	3.9	36
113	Peroxisome Proliferator-Activated Receptor-Î± Activation Reduces Salt-Dependent Hypertension During Chronic Endothelin B Receptor Blockade. Hypertension, 2005, 46, 366-371.	1.3	35
114	Effects of chronic cytochrome P-450 inhibition on the course of hypertension and end-organ damage in Ren-2 transgenic rats. Vascular Pharmacology, 2007, 47, 145-159.	1.0	35
115	Renal mechanisms contributing to the antihypertensive action of soluble epoxide hydrolase inhibition in Renâ€2 transgenic rats with inducible hypertension. Journal of Physiology, 2011, 589, 207-219.	1.3	35
116	Cytochrome P450 epoxygenase-derived epoxyeicosatrienoic acids contribute to insulin sensitivity in mice and in humans. Diabetologia, 2017, 60, 1066-1075.	2.9	35
117	Salt-Sensitive Hypertension After Exposure to Angiotensin Is Associated With Inability to Upregulate Renal Epoxygenases. Hypertension, 2003, 42, 775-780.	1.3	34
118	Role of cytochrome<i>P</i>-450 metabolites in the regulation of renal function and blood pressure in 2-kidney 1-clip hypertensive rats. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2011, 300, R1468-R1475.	0.9	34
119	Epoxyeicosatrienoic acid analog attenuates angiotensin II hypertension and kidney injury. Frontiers in Pharmacology, 2014, 5, 216.	1.6	34
120	Epoxyeicosanoids in Hypertension. Physiological Research, 2019, 68, 695-704.	0.4	34
121	Endothelin antagonism prevents early EGFR transactivation but not increased matrix metalloproteinase activity in diabetes. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2006, 290, R435-R441.	0.9	32
122	P2X Receptor-Stimulated Calcium Responses in Preglomerular Vascular Smooth Muscle Cells Involves 20-Hydroxyeicosatetraenoic Acid. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 1211-1217.	1.3	31
123	Elevated arterial pressure impairs autoregulation independently of AT1 receptor activation. Journal of Hypertension, 2004, 22, 811-818.	0.3	30
124	14,15-Epoxyeicosa-5,8,11-trienoic Acid (14,15-EET) Surrogates: Carboxylate Modifications. Journal of Medicinal Chemistry, 2014, 57, 6965-6972.	2.9	30
125	Heterogeneous activation mechanisms in the renal microvasculature. Kidney International, 1998, 54, S17-S21.	2.6	28
126	Neuronal Nitric Oxide Synthase-Dependent Afferent Arteriolar Function in Angiotensin II-Induced Hypertension. Hypertension, 1999, 33, 462-466.	1.3	28

#	Article	IF	Citations
127	Epoxyeicosatrienoic acid analogue mitigates kidney injury in a rat model of radiation nephropathy. Clinical Science, 2016, 130, 587-599.	1.8	28
128	L-type calcium channels in the renal microcirculatory response to endothelin. American Journal of Physiology - Renal Physiology, 2005, 288, F771-F777.	1.3	27
129	The Renal Microcirculation. , 2008, , 550-683.		27
130	Novel Omega-3 Fatty Acid Epoxygenase Metabolite Reduces Kidney Fibrosis. International Journal of Molecular Sciences, 2016, 17, 751.	1.8	27
131	Two pharmacological epoxyeicosatrienoic acid-enhancing therapies are effectively antihypertensive and reduce the severity of ischemic arrhythmias in rats with angiotensin II-dependent hypertension. Journal of Hypertension, 2018, 36, 1326-1341.	0.3	26
132	Calcium and chloride channel activation by angiotensin II-AT1 receptors in preglomerular vascular smooth muscle cells. American Journal of Physiology - Renal Physiology, 2005, 289, F760-F767.	1.3	25
133	Telmisartan Provides Better Renal Protection Than Valsartan in a Rat Model of Metabolic Syndrome. American Journal of Hypertension, 2011, 24, 816-821.	1.0	25
134	Soluble Epoxide Hydrolase Inhibition Exhibits Antihypertensive Actions Independently of Nitric Oxide in Mice with Renovascular Hypertension. Kidney and Blood Pressure Research, 2012, 35, 595-607.	0.9	25
135	OBESITY INDUCED RENAL OXIDATIVE STRESS CONTRIBUTES TO RENAL INJURY IN SALTâ€SENSITIVE HYPERTENSION. Clinical and Experimental Pharmacology and Physiology, 2009, 36, 724-728.	0.9	24
136	Azilsartan Decreases Renal and Cardiovascular Injury in the Spontaneously Hypertensive Obese Rat. Cardiovascular Drugs and Therapy, 2014, 28, 313-322.	1.3	23
137	Epoxyeicosatrienoic acid analog attenuates the development of malignant hypertension, but does not reverse it once established. Journal of Hypertension, 2016, 34, 2008-2025.	0.3	22
138	Age-related alterations in NOS and oxidative stress in mesenteric arteries from male and female rats. Journal of Applied Physiology, 2004, 97, 1268-1274.	1.2	21
139	Cytochrome P450 epoxygenases provide a novel mechanism for penile erection. FASEB Journal, 2006, 20, 539-541.	0.2	21
140	Increased Renal Proximal Convoluted Tubule Transport Contributes to Hypertension in Cyp4a14 Knockout Mice. Nephron Physiology, 2009, 113, p23-p28.	1.5	21
141	Intrarenal cytochrome P-450 metabolites of arachidonic acid in the regulation of the nonclipped kidney function in two-kidney, one-clip Goldblatt hypertensive rats. Journal of Hypertension, 2010, 28, 582-593.	0.3	21
142	Cytochrome P450 and Lipoxygenase Metabolites on Renal Function. , 2015, 6, 423-441.		21
143	Soluble epoxide hydrolase in podocytes is a significant contributor to renal function under hyperglycemia. Biochimica Et Biophysica Acta - General Subjects, 2017, 1861, 2758-2765.	1.1	21
144	Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1Î± via downregulation of prolyl hydroxylase 3. American Journal of Physiology - Heart and Circulatory Physiology, 2018, 315, H1148-H1158.	1.5	21

#	Article	IF	Citations
145	Postglomerular vasoconstriction to angiotensin II and norepinephrine depends on intracellular calcium release. General Pharmacology, 2000, 34, 409-415.	0.7	20
146	Captopril attenuates hypertension and renal injury induced by the vascular endothelial growth factor inhibitor sorafenib. Clinical and Experimental Pharmacology and Physiology, 2012, 39, 454-461.	0.9	20
147	Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: Studies in Cyp1a1-Ren-2 transgenic rats. Clinical and Experimental Pharmacology and Physiology, 2014, 41, 1003-1013.	0.9	20
148	A dual farnesoid X receptor/soluble epoxide hydrolase modulator treats non-alcoholic steatohepatitis in mice. Biochemical Pharmacology, 2019, 166, 212-221.	2.0	20
149	Antihypertensive action of soluble epoxide hydrolase inhibition in <scp>R</scp>enâ€2 transgenic rats is mediated by suppression of the intrarenal reninâ€“angiotensin system. Clinical and Experimental Pharmacology and Physiology, 2013, 40, 273-281.	0.9	19
150	Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. Journal of Hypertension, 2013, 31, 321-332.	0.3	19
151	Azilsartan Improves Glycemic Status and Reduces Kidney Damage in Zucker Diabetic Fatty Rats. American Journal of Hypertension, 2014, 27, 1087-1095.	1.0	19
152	Tumour necrosis factorâ€‹<i>Î±</i> contributes to improved cardiac ischaemic tolerance in rats adapted to chronic continuous hypoxia. Acta Physiologica, 2015, 214, 97-108.	1.8	19
153	Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats. Clinical Science, 2019, 133, 939-951.	1.8	19
154	The Bradykinin B2 receptor is required for full expression of renal COX-2 and renin. Peptides, 2003, 24, 1141-1147.	1.2	18
155	The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension. Pharmaceuticals, 2009, 2, 217-227.	1.7	18
156	Regulation of Cardiac Mast Cell Maturation and Function by the Neurokinin-1 Receptor in the Fibrotic Heart. Scientific Reports, 2019, 9, 11004.	1.6	18
157	Dual soluble epoxide hydrolase inhibitor/PPAR-Î³ agonist attenuates renal fibrosis. Prostaglandins and Other Lipid Mediators, 2020, 150, 106472.	1.0	18
158	Adaptations of the Renal Microcirculation to Hypertension. Microcirculation, 2002, 9, 315-328.	1.0	18
159	IL6 Suppression Provides Renal Protection Independent of Blood Pressure in a Murine Model of Salt-Sensitive Hypertension. Kidney and Blood Pressure Research, 2007, 30, 195-202.	0.9	17
160	11,12,20-Trihydroxy-eicosa-8(<i>Z</i>)-enoic acid: a selective inhibitor of 11,12-EET-induced relaxations of bovine coronary and rat mesenteric arteries. American Journal of Physiology - Heart and Circulatory Physiology, 2012, 302, H1574-H1583.	1.5	17
161	The epoxyeicosatrienoic acid analog PVPA ameliorates cyclosporine-induced hypertension and renal injury in rats. American Journal of Physiology - Renal Physiology, 2016, 311, F576-F585.	1.3	17
162	Epoxyeicosatrienoic Acid Analog EET-A Blunts Development of Lupus Nephritis in Mice. Frontiers in Pharmacology, 2019, 10, 512.	1.6	17

#	Article	IF	Citations
163	Epoxy Fatty Acids: From Salt Regulation to Kidney and Cardiovascular Therapeutics. Hypertension, 2020, 76, 3-15.	1.3	16
164	ATP-mediated Ca2+signaling in preglomerular smooth muscle cells. American Journal of Physiology - Renal Physiology, 1999, 276, F450-F456.	1.3	15
165	20-HETE or EETs: which arachidonic acid metabolite regulates proximal tubule transporters and contributes to pressure natriuresis?. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2004, 287, R3-R5.	0.9	14
166	Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. Vascular Pharmacology, 2007, 46, 144-151.	1.0	14
167	Regulation of ENaC-Mediated Sodium Reabsorption by Peroxisome Proliferator-Activated Receptors. PPAR Research, 2010, 2010, 1-9.	1.1	14
168	Orally active epoxyeicosatrienoic acid analog does not exhibit antihypertensive and reno- or cardioprotective actions in two-kidney, one-clip Goldblatt hypertensive rats. Vascular Pharmacology, 2015, 73, 45-56.	1.0	14
169	Altered Renal Vascular Responsiveness to Vasoactive Agents in Rats with Angiotensin II-Dependent Hypertension and Congestive Heart Failure. Kidney and Blood Pressure Research, 2019, 44, 792-809.	0.9	14
170	20-Hydroxyeicosatetraenoic acid antagonist attenuates the development of malignant hypertension and reverses it once established: a study in Cyp1a1-Ren-2 transgenic rats. Bioscience Reports, 2018, 38, .	1.1	13
171	Epoxyeicosatrienoic Acid-Based Therapy Attenuates the Progression of Postischemic Heart Failure in Normotensive Sprague-Dawley but Not in Hypertensive Ren-2 Transgenic Rats. Frontiers in Pharmacology, 2019, 10, 159.	1.6	13
172	Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity. International Journal of Molecular Sciences, 2021, 22, 2793.	1.8	13
173	Epoxylipids and soluble epoxide hydrolase in heart diseases. Biochemical Pharmacology, 2022, 195, 114866.	2.0	13
174	Combined treatment with epoxyeicosatrienoic acid analog and 20-hydroxyeicosatetraenoic acid antagonist provides substantial hypotensive effect in spontaneously hypertensive rats. Journal of Hypertension, 2020, 38, 1802-1810.	0.3	12
175	Inactivation of p66Shc Decreases Afferent Arteriolar KATP Channel Activity and Decreases Renal Damage in Diabetic Dahl SS Rats. Diabetes, 2018, 67, 2206-2212.	0.3	11
176	Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation. Biomedicines, 2021, 9, 1053.	1.4	11
177	Adaptations of the renal microcirculation to hypertension. Microcirculation, 2002, 9, 315-28.	1.0	11
178	Kidney in the net of acute and long-haul coronavirus disease 2019: a potential role for lipid mediators in causing renal injury and fibrosis. Current Opinion in Nephrology and Hypertension, 2022, 31, 36-46.	1.0	11
179	The Roles of Intrarenal 20-Hydroxyeicosatetraenoic and Epoxyeicosatrienoic Acids in the Regulation of Renal Function in Hypertensive Ren-2 Transgenic Rats. Kidney and Blood Pressure Research, 2007, 30, 335-346.	0.9	10
180	Combined Inhibition of Soluble Epoxide Hydrolase and Renin-Angiotensin System Exhibits Superior Renoprotection to Renin-Angiotensin System Blockade in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats with Established Chronic Kidney Disease. Kidney and Blood Pressure Research, 2018, 43, 329-349.	0.9	10

#	Article	IF	Citations
181	CYP450, COX-2 and Obesity Related Renal Damage. Toxicology Mechanisms and Methods, 2005, 15, 125-136.	1.3	9
182	Afferent arteriolar responses to Î²,Î³-methylene ATP and 20-HETE are not blocked by ENaC inhibition. Physiological Reports, 2013, 1, e00082.	0.7	9
183	Characterization of Dahl salt-sensitive rats with genetic disruption of the A2B adenosine receptor gene: implications for A2B adenosine receptor signaling during hypertension. Purinergic Signalling, 2015, 11, 519-531.	1.1	9
184	Pharmacological Blockade of Soluble Epoxide Hydrolase Attenuates the Progression of Congestive Heart Failure Combined With Chronic Kidney Disease: Insights From Studies With Fawn-Hooded Hypertensive Rats. Frontiers in Pharmacology, 2019, 10, 18.	1.6	9
185	Loss of Chloride Channel 6 (CLC-6) Affects Vascular Smooth Muscle Contractility and Arterial Stiffness via Alterations to Golgi Calcium Stores. Hypertension, 2021, 77, 582-593.	1.3	9
186	Interlobular Arteries From 2-Kidney, 1-Clip Goldblatt Hypertensive Ratsâ€™ Exhibit-Impaired Vasodilator Response to Epoxyeicosatrienoic Acids. American Journal of the Medical Sciences, 2016, 351, 513-519.	0.4	8
187	Role of the cytochrome P-450/ epoxyeicosatrienoic acids pathway in the pathogenesis of renal dysfunction in cirrhosis. Nephrology Dialysis Transplantation, 2018, 33, 1333-1343.	0.4	8
188	Editorial: Clinical Paths for Soluble Epoxide Hydrolase Inhibitors. Frontiers in Pharmacology, 2020, 11, 598858.	1.6	8
189	Multi-Target Drugs for Kidney Diseases. Kidney360, 2021, 2, 1645-1653.	0.9	8
190	Replacement of Lost Substance P Reduces Fibrosis in the Diabetic Heart by Preventing Adverse Fibroblast and Macrophage Phenotype Changes. Cells, 2021, 10, 2659.	1.8	8
191	Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats. Frontiers in Physiology, 2021, 12, 622882.	1.3	7
192	Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats. British Journal of Pharmacology, 2021, 178, 4468-4484.	2.7	6
193	SARS-CoV-2 spike protein causes cardiovascular disease independent of viral infection. Clinical Science, 2022, 136, 431-434.	1.8	6
194	Epigenetic soluble epoxide hydrolase regulation causes endothelial dysfunction. Acta Physiologica, 2019, 225, e13203.	1.8	5
195	Ramatroban for chemoprophylaxis and treatment of COVID-19: David takes on Goliath. Expert Opinion on Therapeutic Targets, 2022, 26, 13-28.	1.5	5
196	Soluble epoxide hydrolase contamination of specific catalase preparations inhibits epoxyeicosatrienoic acid vasodilation of rat renal arterioles. American Journal of Physiology - Renal Physiology, 2011, 301, F765-F772.	1.3	4
197	Radiation-induced afferent arteriolar endothelial-dependent dysfunction involves decreased epoxygenase metabolites. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 310, H1695-H1701.	1.5	4
198	The effect of compound DM509 on kidney fibrosis in the conditions of the experimental model. Bulletin of Taras Shevchenko National University of Kyiv Series Biology, 2020, 80, 10-15.	0.1	4

#	Article	IF	Citations
199	Epoxyeicosatrienoic Acid Analog and 20-HETE Antagonist Combination Prevent Hypertension Development in Spontaneously Hypertensive Rats. Frontiers in Pharmacology, 2021, 12, 798642.	1.6	4
200	Dual sEH/COX-2 Inhibition Using PTUPBâ€"A Promising Approach to Antiangiogenesis-Induced Nephrotoxicity. Frontiers in Pharmacology, 2021, 12, 744776.	1.6	4
201	Addition of Endothelin A-Receptor Blockade Spoils the Beneficial Effect of Combined Renin-Angiotensin and Soluble Epoxide Hydrolase Inhibition: Studies on the Course of Chronic Kidney Disease in 5/6 Nephrectomized Ren-2 Transgenic Hypertensive Rats. Kidney and Blood Pressure Research, 2019, 44, 1493-1505.	0.9	3
202	Prospects for Clinical Development of Stat5 Inhibitor IST5-002: High Transcriptomic Specificity in Prostate Cancer and Low Toxicity In Vivo. Cancers, 2020, 12, 3412.	1.7	3
203	Molecular Pathways in Hypertensive Renal Damage. Updates in Hypertension and Cardiovascular Protection, 2018, , 445-463.	0.1	3
204	Tim-1 Deficiency Aggravates High-Fat Diet-Induced Steatohepatitis in Mice. Frontiers in Immunology, 2021, 12, 747794.	2.2	3
205	Physiological roles of soluble epoxide hydrolase and therapeutic prospects of its inhibition. FASEB Journal, 2006, 20, .	0.2	3
206	Editorial: Interactions Between Podocytes, Mesangial Cells, and Glomerular Endothelial Cells in Glomerular Diseases. Frontiers in Physiology, 2022, 13, 849693.	1.3	3
207	Adenosine 2A Receptors and Epoxyeicosatrienoic Acids. Hypertension, 2009, 54, 1223-1225.	1.3	2
208	20-Hydroxyeicosatetraenoic Acid and Angiotensin. Hypertension, 2010, 56, 822-823.	1.3	2
209	Ether epoxyeicosatrienoic acid (EET) analogs lower blood pressure when administered inâ€vivo to the spontaneously hypertensive rats. FASEB Journal, 2008, 22, 479.44.	0.2	2
210	Eicosanoid Inhibitors as Therapeutic Targets for Metabolic Syndrome Related Kidney Disease. Current Enzyme Inhibition, 2006, 2, 73-77.	0.3	1
211	Renal blood flow autoregulation: what are the contributions for nitric oxide or superoxide to modulate the myogenic response?. American Journal of Physiology - Renal Physiology, 2016, 310, F1013-F1015.	1.3	1
212	Mitigation of normal tissue radiation injury: evidence from rat radiation nephropathy models. Journal of Radiation Oncology, 2016, 5, 1-8.	0.7	1
213	Diabetes risk associated with plasma epoxylipid levels. EBioMedicine, 2021, 66, 103331.	2.7	1
214	A Dual Soluble Epoxide Hydrolase Inhibitor/PPARâ€Î³ Agonist Prevents Renal Fibrosis in Mouse Unilateral Ureteral Obstruction Model. FASEB Journal, 2019, 33, 678.12.	0.2	1
215	Elevated Aminopeptidase P Attenuates Cerebral Arterial Responses to Bradykinin in Fawn-Hooded Hypertensive Rats. PLoS ONE, 2015, 10, e0145335.	1.1	1
216	A sorafenib-induced model of glomerular kidney disease. Bulletin of Taras Shevchenko National University of Kyiv Series Biology, 2020, 81, 25-31.	0.1	1

#	Article	IF	Citations
217	Ureaâ€based soluble epoxide hydrolase inhibitors dilate mesenteric resistance vessels. FASEB Journal, 2006, 20, A669.	0.2	1
218	Soluble Epoxide Hydrolase Inhibition Modulates Gene Expression of Antiâ€Apoptotic and Apoptotic Factors. FASEB Journal, 2008, 22, 733.11.	0.2	1
219	Reply to â€œLetter to the editor: â€˜Concern regarding quantification of urinary nephrin by commercially available ELISAâ€™â€. American Journal of Physiology - Renal Physiology, 2015, 309, F271-F271.	1.3	0
220	SP074SOLUBLE EPOXIDE HYDROLASE INHIBITION AUGMENTS RAS BLOCKADE RENOPROTECTION INSUBTOTALLY NEPHRECTOMIZED REN-2 TRANSGENIC HYPERTENSIVE RATS WITH CHRONIC KIDNEY DISEASE. Nephrology Dialysis Transplantation, 2018, 33, i370-i370.	0.4	0
221	Editorial: Renal Function in Acute and Chronic Kidney Diseases. Frontiers in Physiology, 2020, 11, 625353.	1.3	0
222	Dietary fat increases renal injury in SHR in the absence of changes in insulin sensitivity or blood pressure. FASEB Journal, 2007, 21, A1194.	0.2	0
223	Rosaglitazone (RGZ) decreases renal damage in spontaneously diabetic Gotoâ€Kakizaki (GK) rats. FASEB Journal, 2007, 21, A1194.	0.2	0
224	Peroxisome proliferatorsâ€activated receptorâ€alpha activation increases renal CYP2C23 and decreases cyclin D1 and blood pressure in Zucker diabetic fatty rats. FASEB Journal, 2007, 21, A842.	0.2	0
225	Longâ€term high fat diet treatment activates NF kappa B signaling and increases endothelial dysfunction in angiotensin II hypertensive rats. FASEB Journal, 2007, 21, A1196.	0.2	0
226	High fat diet induces insulin resistance and heightened renal inflammation in angiotensin II hypertensive rats. FASEB Journal, 2007, 21, A504.	0.2	0
227	Soluble Epoxide Inhibition Differentially Modulates Flow Induced Vascular Remodeling in Spontaneously Hypertensive Stroke Prone Rats and Wistar Kyoto Rats. FASEB Journal, 2008, 22, 479.42.	0.2	0
228	Soluble epoxide hydrolase inhibition attenuates the development of renovascular hypertension in 2K1C rats.. FASEB Journal, 2008, 22, 479.7.	0.2	0
229	Simvastatin and Tempol Protect Against Endothelial Dysfunction and Renal Injury in a Model of Obesity and Hypertension. FASEB Journal, 2008, 22, 947.8.	0.2	0
230	Soluble epoxide hydrolase inhibitor improves cardiac ischemic tolerance in Renâ€2 transgenic rats. FASEB Journal, 2008, 22, 479.6.	0.2	0
231	The divergent role of epoxyeicosatrienoic acids in the regulation of renal function in normotensive and twoâ€kidney oneâ€clip Goldblatt hypertensive rats. FASEB Journal, 2008, 22, 761.1.	0.2	0
232	SPARC deficiency ameliorates renal damage resulting from angiotensin II and a high salt diet. FASEB Journal, 2009, 23, 604.1.	0.2	0
233	Renal mechanisms of antihypertensive effects caused by inhibition of soluble epoxide hydrolase in Cyp1a1â€Renâ€2 transgenic rats.. FASEB Journal, 2009, 23, 1016.4.	0.2	0
234	LCâ€MS measurement of the epoxyeicosatrienoic acid mimetic EETâ€8â€ZEâ€D in rat serum. FASEB Journal, 2009, 23, 1019.13.	0.2	0

#	Article	IF	Citations
235	Development of combined soluble epoxide hydrolase inhibitors and epoxide analogs with vasodilator activity. FASEB Journal, 2009, 23, 766.2.	0.2	0
236	Epoxyeicosatrienoic acids (EET) contribute to flowâ€induced dilation in mice mesenteric resistance artery. FASEB Journal, 2009, 23, 932.1.	0.2	0
237	Impaired mesenteric resistance artery relaxation to KATP channel activation in cardiometabolic syndrome is improved by rosiglitazone treatment. FASEB Journal, 2010, 24, 978.9.	0.2	0
238	Soluble Epoxide Hydrolase Inhibition (SEHi) and Thiazolidinedione (TZD) in combination provide greater renal injury protection in Spontaneously Hypertensive Obese (SHROB) Rats.. FASEB Journal, 2010, 24, 812.9.	0.2	0
239	Attenuated endothelinâ€1 (ETâ€1) vasoconstrictor responses in cardiometabolic syndrome are attributed to increased ETâ€B receptors. FASEB Journal, 2010, 24, 978.10.	0.2	0
240	Vascular Endothelial Growth Factor (VEGF) Inhibitors Induce Hypertension, Afferent Arteriolar Dysfunction, and Glomerular Injury. FASEB Journal, 2010, 24, 575.9.	0.2	0
241	CYP Pathway Modulators Alter Development and Angiogenesis in Zebrafish Embryos. FASEB Journal, 2011, 25, lb437.	0.2	0
242	Deletion of soluble epoxide hydrolase gene improves renal endothelial function and reduces renal inflammation and injury in streptozotocinâ€induced type 1 diabetes. FASEB Journal, 2011, 25, 664.10.	0.2	0
243	Soluble epoxide hydrolase deficiency alters pancreatic islet size and improves glucose homeostasis in a model of insulin resistance.. FASEB Journal, 2012, 26, 686.4.	0.2	0
244	Novel Orally Active Epoxyeicosatrienoic Acid (EET) Analogs Attenuate Cisplatin Nephrotoxicity. FASEB Journal, 2012, 26, 851.7.	0.2	0
245	A novel epoxyeicosatrienoic acid analog attenuates hypertension and renal injury in Cyp2c44 KO mice. FASEB Journal, 2013, 27, 880.1.	0.2	0
246	A dual COXâ€sEH inhibitor improved glycemic status and reduced kidney injury in Zucker diabetic fatty rat (689.4). FASEB Journal, 2014, 28, 689.4.	0.2	0
247	Radiation Nephropathy is Mitigated by Epoxyeicosatrienoic acid Analog. FASEB Journal, 2015, 29, 938.4.	0.2	0
248	The Effect of Voltageâ€Sensitive Chloride Channel 6 on Development of Saltâ€Sensitive Hypertension. FASEB Journal, 2018, 32, 750.23.	0.2	0
249	Glomerular Mesangial Proliferation is Mitigated by sEH/COXâ€2 Dualâ€Inhibition. FASEB Journal, 2019, 33, 671.7.	0.2	0
250	A Dual Farnesoid X Receptor Agonist /Soluble Epoxide Hydrolase Inhibitor Prevents Nonâ€Alcoholic Steatohepatitis in Mice. FASEB Journal, 2019, 33, 506.3.	0.2	0
251	EET Analogs and the Dualâ€Inhibition of sEH/COXâ€2 for the Treatment of Focal Segmental Glomerular Sclerosis. FASEB Journal, 2019, 33, 863.8.	0.2	0
252	A Novel Dual Soluble Epoxide Hydrolase Inhibitor/Cyclooxygenaseâ€2 Inhibitor Treats Type 2 Diabetic Complications in Obese ZSF1 Rats. FASEB Journal, 2019, 33, 514.2.	0.2	0

#	Article	IF	Citations
253	COMBINED FARNESOID X RECEPTOR AGONIST AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR TREATS PROGRESSIVE RENAL FIBROSIS. FASEB Journal, 2020, 34, 1-1.	0.2	0
254	REVERSAL OF UNILATERAL URETERAL OBSTRUCTION LEADS TO SALTâ€SENSITIVE HYPERTENSION. FASEB Journal, 2020, 34, 1-1.	0.2	0
255	DUAL ACTING COXâ€2 AND SOLUBLE EPOXIDE HYDROLASE INHIBITOR ATTENUATES GLOMERULAR INJURY IN FOCAL SEGMENTAL GLOMERULAR SCLEROSIS. FASEB Journal, 2020, 34, 1-1.	0.2	0
256	Effective Antihypertensive Treatment with Epoxyeicosatrienoic Acid Analog (EETâ€A) and 20â€HETE Antagonist (AAA) of Spontaneously Hypertensive Rats (SHR). FASEB Journal, 2020, 34, 1-1.	0.2	0
257	A DUAL COXâ€2/sEH INHIBITOR TREATED KIDNEY INJURY IN A DRUGâ€INDUCED GLOMERULAR DISEASE MODEL. FASEB Journal, 2020, 34, 1-1.	0.2	0
258	Fructose Consumption Increases Blood Pressure and Induces Changes in Renal Microvascular Function. FASEB Journal, 2020, 34, 1-1.	0.2	0
259	Abstract P056: Voltage-gated Chloride Channel 6 Regulates Intracellular Calcium Signaling In Vascular Smooth Muscle Cells And Prevents Arterial Stiffening. Hypertension, 2020, 76, .	1.3	0
260	Orally active epoxyeicosatrienoic acid analogs in hypertension and renal injury. Advances in Pharmacology, 2022, , .	1.2	0
261	Abstract 10030: A Novel Multi-Target Drug Prevents Cancer Therapy-Induced Hypertension and Renal Damage. Circulation, 2021, 144, .	1.6	0